Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
The Synlogic, Inc. (SYBX) news page on Stock Titan provides a focused view of company announcements, financial updates and strategic developments for this biopharmaceutical issuer. Synlogic has described itself as a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics based on engineered probiotics, with programs historically centered on serious and rare metabolic diseases.
News items for SYBX commonly include quarterly and annual financial results, where Synlogic reports its cash position, research and development expenses, general and administrative expenses and net income or loss. These releases often explain how changes in spending relate to clinical programs, restructuring decisions and collaboration revenue from partners such as Roche or from agreements like material transfer arrangements.
Another key category of Synlogic news covers clinical and scientific milestones. Examples include updates on pivotal studies such as Synpheny-3 in phenylketonuria, announcements about the discontinuation of that trial, and publications of preclinical and clinical data for candidates like SYNB1353 in classical homocystinuria. These stories highlight proof-of-mechanism findings, safety and tolerability observations and the company’s use of dietary disease models and GI-restricted drug candidates.
Corporate and strategic communications form a third important news stream. Synlogic has issued press releases about adopting a limited duration stockholder rights plan, engaging financial advisors to explore strategic alternatives, implementing a substantial workforce reduction and ceasing operations while it evaluates options such as mergers, acquisitions, asset sales or other transactions. Additional items include contract awards, such as the subcontract with the Air Force Research Laboratory to develop a manufacturing process for a potential live probiotic product.
Investors, analysts and researchers can use the SYBX news feed to follow how Synlogic’s financial profile, clinical programs, collaborations and strategic review process evolve over time. Regularly reviewing these updates helps place the company’s Synthetic Biotic platform and stock performance in the context of its disclosed operational and strategic decisions.
Synlogic, Inc. (Nasdaq: SYBX) announced its presentation of a poster on SYNB8802, an investigational Synthetic Biotic for treating Enteric Hyperoxaluria, at the ASN Kidney Week from Oct. 22-25, 2020.
The poster details the engineering of SYNB8802 to metabolize oxalate in the gastrointestinal tract, aimed at reducing urinary oxalate levels and associated kidney damage. This product is progressing into human clinical studies to evaluate its safety and effectiveness.
Synlogic (Nasdaq: SYBX), a clinical-stage company, announced on September 14, 2020, the appointment of David Hava, Ph.D. as Chief Scientific Officer. Dr. Hava brings over a decade of R&D experience, having previously served as CSO at Metera Pharmaceuticals and Pulmatrix. He will lead research initiatives and expand Synlogic's portfolio of partnerships. The leadership change is expected to enhance the company's Synthetic Biotic platform aimed at treating metabolic disorders and potentially other diseases.
Synlogic (Nasdaq: SYBX) announced its participation in several upcoming virtual banking conferences, aimed at highlighting its advancements in synthetic biology and therapeutic developments.
The conferences include:
- HC Wainwright 22nd Annual Global Investor Conference on September 15, 2020, at 12:00 PM.
- Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 23, 2020, at 4:10 PM.
- Jefferies IBD Therapeutics Summit on September 23, 2020, at a time to be determined.
Webcasts will be available on the company's website.
Synlogic, Inc. (SYBX) reported its Q2 2020 financial results, highlighting a cash balance of $109.1 million. The company incurred a net loss of $15.5 million, or $0.44 per share, slightly worsening from $12.3 million, or $0.45 per share, in Q2 2019. Revenue remained flat at $0.4 million, primarily from a former partnership with AbbVie. Synlogic is advancing its clinical pipeline, with plans to initiate a Phase 2 trial for SYNB1618 in phenylketonuria and IND-enabling studies for SYNB8802 by early 2021. The company expects a cash runway into 2022.
Synlogic (Nasdaq: SYBX) announced its participation in upcoming virtual banking conferences on August 10 and August 12, 2020. CEO Aoife Brennan will feature in a 'Fireside Chat' during the BTIG Virtual Biotechnology Conference at 2:00 pm on August 10, followed by a presentation at the Wedbush PacGrow Healthcare Virtual Conference at 3:30 pm on August 12. Live webcasts will be available on the company’s website, with recordings accessible for 30 days post-event. Synlogic focuses on synthetic biology to develop innovative therapies for metabolic disorders.
Synlogic, Inc. (Nasdaq: SYBX) announced the promotion of Antoine 'Tony' Awad to Chief Operating Officer, effective immediately. Awad will oversee the company's development, manufacturing, and supply chain operations, reinforcing the company's focus on synthetic biology medicines. His promotion is seen as a recognition of his contributions and highlights the importance of manufacturing for future growth. Additionally, Andrew Marsh was appointed Head of Development Operations, adding further expertise to Synlogic's leadership team as the company advances its pipeline of Synthetic Biotic medicines.
Synlogic, Inc. (Nasdaq: SYBX) revealed it will announce its second quarter 2020 financial results on August 6, 2020. The announcement will be followed by a public conference call at 8:00 am ET. The call, accessible via telephone and webcast, will provide insights into the company's financial results and corporate updates. Synlogic specializes in synthetic biology, focusing on therapeutics for metabolic disorders and developing a pipeline for immunology and oncology therapies.